First Report of NDM-1-Producing Acinetobacter guillouiae by Bošnjak, Zrinka et al.
  
    
 
Središnja medicinska knjižnica 
 
 
 
 
Bošnjak Z., Plečko V., Budimir A., Mareković I., Bedenić B. (2014) First 
Report of NDM-1-Producing Acinetobacter guillouiae. Chemotherapy, 
60 (4). pp. 250-2. ISSN 0009-3157 
 
 
http://www.karger.com/che 
 
http://dx.doi.org/10.1159/000381256 
 
 
 
 
 
http://medlib.mef.hr/2610 
 
 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/ 
   
 
 
 
 
 
FIRST REPORT OF NDM-1 PRODUCING ACINETOBACTER GUILLONIAE  
 
 
ABSTRACT 
 
 Since 2014 screening for metallo-β-lactamases (MBLs) of all Acinetobacter spp isolates  by 
phenotypic methods and PCR has been implemented at the University Hospital Center 
Zagreb.  The first MBL positive isolate was identified in Acinetobacter guiolloniae. The strain 
was isolated from drain of a newborn child hospitalized in a paediatric intensive care unit for 
heart malformation and identified as Acinetobacter guiolloniae with Maldi Tof automated 
system. The child was teated with meropenem and vancomycin prior to isolation of this strain.  
The strain was resistant to meropenem, imipenem, ceftazidime, cefotaxime, ceftriaxone, 
cefepime, gentamicin and ciprofloxacin and sulbactam/ampicillin, intermediate susceptible  to 
piperacillin/tazobactam, and susceptible to colistin. Hodge test and combined disk test with 
EDTA were positive indicating the production of MBL. PCR and sequencing revealed blaOXA-
58 and blaNDM-1 genes.  This is the first report of NDM-1 in Acinetobacter spp in Croatia. Early 
detection of these genes will help in prevention and adequate infection control by limiting the 
spread of these organisms.  
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To the editor:  Acinetobacter spp is  an opportunistic pathogen with increasing relevance in 
nosocomial infections (1-2).  It is often associated with pneumonia, septicemia, urinary tract 
infections, wound infections and meningitis. Carbapenem-resistant strains have been reported 
all over the world. The first outbreak of carbapenem-resistant Acinetobacter baumannii 
isolates in Croatia has been documented in Split University Hospital (3). As demonstrated 
later, the carbapenem-resistance was mediated by hyperproduction of OXA-51 due the 
ISAba1 location upstream of the genes (4). Later, the studies of carbapenem-resistance in 
Croatia have reported the emergence of  OXA-23, OXA-58 and OXA-72 producing strains  in 
different hospital centers in Croatia (5-7) but no metallo-β-lactamases (MBL) were reported.  
Since 2014 screening for  (MBLs) of all Acinetobacter spp isolates by phenotypic methods 
and PCR has been implemented at the University Hospital Center Zagreb.  The first MBL  
was identified in Acinetobacter guiolloniae. The strain was isolated from drain of a newborn 
child hospitalized in a paediatric intensive care unit for heart malformation and identified as 
A.  guiolloniae with Maldi Tof automated system. The child was teated with meropenem and 
vancomycin prior to isolation of this strain.  
Antimicrobial drug susceptibility testing was performed  by Vitex2 (bioMeriux, Marcy-
l'Etoile, France) and broth micodilution test and interpreted according to CLSI (8). The strain 
was resistant to meropenem (MIC= 32 µg/ml),  ceftazidime, cefotaxime, ceftriaxone, cefepim 
and sulbactam/ampicillin with MIC of >128 µg/ml, gentamicin (MIC=8 mg/L) and 
ciprofloxacin (MIC=4 µg/ml),  intermediate susceptible to piperacillin/tazobactam (MIC= 64 
µg/mL) and imipenem (8 µg/ml), and susceptible to amikacin (MIC=2 µg/ml) and  colistin 
(MIC=0.25 µg/ml). Hodge test and combined disk test with EDTA were positive indicating 
the production of MBL. MICs of meropenem and imipenem were not reduced by cloxacillin 
indicating that chromosomal AmpC β-lactamase did not affect susceptibility to carbapenems,  
but small reduction of two dilutions was observed after addition of  sodium chloride 
indicating the production of OXA-58.  Combined disk test with clavulanic acid was negative 
which is consistent with the absence of ESBL. PCR and sequencing of chromosomal DNA 
from boiled colonies revealed blaOXA-58 and blaNDM-1 genes. Plasmid was extracted with 
Qiagen Mini kit (Inel, Zagreb, Croatia) and subjected to PCR with primers specific for 
blaOXA-58 and blaNDM-1 gene but yielded no product indicating chromosomal origin of the 
genes.  Incompatibility group of the plasmids described in A. baumannii was determined by 
multiplex PCR with six primer pairs covering 19 homology groups according to Bertini et al. 
(9).  Plasmid extraction did not yield any products in mulitiplex PCR for  incompatibility 
groups described so far. Class 1 integron was amplified with primers CSU-F and CSU-R as 
described previously (11). BlaNDM-1 gene was encoded in class 1 integron. This is the first 
report of NDM-1 in Acinetobacter spp in Croatia. Previous studies reported NDM-1 in A. 
baumannii in Czech republic in a patient repatriated from Egypt (11), in Lebanon from 
civilians wounded during the Syrian war (12), in East Africa (13), Iran (14) and Belgium (15).  
Outbreaks associated with NDM-1 positive A. baumannii were described in France (16). In 
India, coexistence of OXA-23 and NDM-1 was reported (17). In our study coproduction of 
NDM-1 and OXA-58 β-lactamase was described.  The presence of ISAba3 upstream of blaOXA-58 
gene promotes the expression of the gene and the level of carbapenem resistance and plays role 
in the mobilization of the gene.   NDM-1 is hydrolyzing virtually all β-lactams but the strain 
was intermediate susceptible to piperacillin/tazobactam and imipenem.  The level of β-lactam 
resistance in MBL positive strains depends on the expression of blaMBL gene and it is possible 
that A. guiolloniae has low level expression of the gene due to low gene copy number or 
weak promotor which results in small amount of enzyme produced.  OXA-58 and NDM-1 β-
lactamases are usually plasmid-mediated (7, 19) but our strain yielded no amplicon with 
plasmid extract indicating chromosomal origin of the β-lactamases. BlaNDM-1 gene did not 
spread to other more pathogenic species in the genus Acinetobacter.  
Due to effective infection control measures the strain did not spread to other patients or other 
hospital units. It was not imported from epidemic country.  NDM-1 was for the first time 
identified in Klebsiella pneumonia isolate in Croatia in 2008 (18) and later spread among 
Enterobacteriaceae (19). MBL-positive Acinetobacter spp isolates are a source of deep concern 
due to their multidrug resistance pattern and the ability of this genus to persist in the environment 
(13).   Early detection of these genes will help in prevention and adequate infection control by 
limiting the spread of these organisms (20). Therapeutic options are often very limited 
particularly since colistin resistant isolates of Acinetobacter spp have emerged recently also in 
Croatia. Colistin combined with other antibiotics such as vancomycin or meropenem is 
recommended for the treatment of infections associated with such pandrug resistant strains (21-
22) 
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